These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 8729587

  • 1. The patient at risk: who should we be treating?
    Shviro I, Leitersdorf E.
    Br J Clin Pract Suppl; 1996 Jan; 77A():24-7. PubMed ID: 8729587
    [Abstract] [Full Text] [Related]

  • 2. The patient at risk: who should we be treating?
    Leitersdorf E.
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [Abstract] [Full Text] [Related]

  • 3. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [Abstract] [Full Text] [Related]

  • 4. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 9. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 10. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS, Mikhailidis DP.
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [Abstract] [Full Text] [Related]

  • 11. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E, Harats D, Gavish D.
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [Abstract] [Full Text] [Related]

  • 13. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE, Davidson M, Jones MR, Abby SL.
    Am J Cardiol; 2006 Apr 15; 97(8):1198-205. PubMed ID: 16616026
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Statins in primary prevention of coronary heart disease].
    Paulweber B.
    Wien Med Wochenschr; 1999 Apr 15; 149(5-6):129-38. PubMed ID: 10408004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2183-92. PubMed ID: 17692154
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, STELLAR Study Group.
    Curr Med Res Opin; 2003 Sep 15; 19(8):689-98. PubMed ID: 14687438
    [Abstract] [Full Text] [Related]

  • 20. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun 15; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.